Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melina Stark

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 27, 2025
Linking higher amyloid beta 1-38 (Aβ(1-38)) levels to reduced Alzheimer's disease progression riskLuisa Sophie Schneider, Silka Dawn Freiesleben, Gerard van Breukelen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 23, 2026
Alpha-synuclein quantitative seed amplification assay predicts conversion to dementiaStefan Bräuer, Verena Sondermann, Iñaki Schniewind, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairmentElizabeth Kuhn, Luca Kleinedam, Melina Stark, et al.
The Journal of Prevention of Alzheimer'S Disease|May 29, 2026
Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairmentElizabeth Kuhn, Luca Kleineidam, Melina Stark, et al.
Neurology|September 20, 2024
Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive DeclineXiao Wang, Silka D Freiesleben, Luisa-Sophie Schneider, et al.
Brain Communications|January 13, 2025
Locus coeruleus signal intensity and emotion regulation in agitation in Alzheimer's diseaseKathy Y Liu, Matthew J Betts, Dorothea Hämmerer, et al.
The Journal of Prevention of Alzheimer'S Disease|March 29, 2026
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's diseaseArda C Cetindag, Carola G Schipke, Hermann Esselmann, et al.
Molecular Psychiatry|April 17, 2025
Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s diseaseDavid Mengel, Ester Soter, Julia Maren Ott, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 13, 2026
Minor neuropsychological deficits and stage 2 of Alzheimer's diseaseMelina Stark, Michael Wagner, Elizabeth Kuhn, et al.
Neurology|October 11, 2023
Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive DeclineMelina Stark, Steffen Wolfsgruber, Luca Kleineidam, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 27, 2025
Linking higher amyloid beta 1-38 (Aβ(1-38)) levels to reduced Alzheimer's disease progression riskLuisa Sophie Schneider, Silka Dawn Freiesleben, Gerard van Breukelen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 23, 2026
Alpha-synuclein quantitative seed amplification assay predicts conversion to dementiaStefan Bräuer, Verena Sondermann, Iñaki Schniewind, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairmentElizabeth Kuhn, Luca Kleinedam, Melina Stark, et al.
The Journal of Prevention of Alzheimer'S Disease|May 29, 2026
Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairmentElizabeth Kuhn, Luca Kleineidam, Melina Stark, et al.
Neurology|September 20, 2024
Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive DeclineXiao Wang, Silka D Freiesleben, Luisa-Sophie Schneider, et al.
Brain Communications|January 13, 2025
Locus coeruleus signal intensity and emotion regulation in agitation in Alzheimer's diseaseKathy Y Liu, Matthew J Betts, Dorothea Hämmerer, et al.
The Journal of Prevention of Alzheimer'S Disease|March 29, 2026
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's diseaseArda C Cetindag, Carola G Schipke, Hermann Esselmann, et al.
Molecular Psychiatry|April 17, 2025
Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s diseaseDavid Mengel, Ester Soter, Julia Maren Ott, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 13, 2026
Minor neuropsychological deficits and stage 2 of Alzheimer's diseaseMelina Stark, Michael Wagner, Elizabeth Kuhn, et al.
Neurology|October 11, 2023
Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive DeclineMelina Stark, Steffen Wolfsgruber, Luca Kleineidam, et al.
Pageof 3